RÉSUMÉ
Granular cell tumor was originally described as granular cell myoblastoma by Abrikossoff. The incidence of GCT in the gastrointestinal tract is low, and most granular cell tumors occur in the esophagus and large bowel. Gastric granular cell tumors are rare and difficult to distinguish from carcinoid tumors by gross endoscopic findings and endoscopic ultrasonography findings. We report a case of gastric granular cell tumor, treated by endoscopic submucosal dissection, and review the endoscopic ultrasonography findings of recently reported gastric granular cell tumors.
Sujet(s)
Tumeur carcinoïde , Endosonographie , Oesophage , Tube digestif , Tumeur à cellules granuleuses , Incidence , EstomacRÉSUMÉ
Primary colorectal lymphoma is a very rare disease entity that accounts for less than 0.2-0.65% of all colon cancers. It is as an extranodal lymphoma of the colon that mainly arises from B cells and primary colorectal lymphoma that arises from T cells is very rare both in Western countries and in Korea. Colonic lymphoma can be classified endoscopically into 5 categories as follows: fungating, ulcerative, infiltrative, ulcerofungating, and ulceroinfiltrative type. The endoscopic features of primary colorectal lymphoma differ according to their cellular origin; about half of B cell lymphomas are fungating type whereas most of T cell lymphomas are of ulcerative or ulceroinfiltrative type. Mass forming primary T cell lymphoma of the colon is extremely rare. Herein, we present a case of primary natural killer like T cell lymphoma of the colon presenting as fungating type with review of literature.
Sujet(s)
Lymphocytes B , Côlon , Côlon ascendant , Tumeurs du côlon , Corée , Lymphomes , Lymphome B , Lymphome T , Maladies rares , Lymphocytes T , UlcèreRÉSUMÉ
Peritonitis is one of the major complications of continuous ambulatory peritoneal dialysis (CAPD). Multidrug-resistant organisms, including vancomycin-resistant enterococci (VRE), have been reported as pathogens of CAPD-associated peritonitis. The incidence of hospital-associated infections caused by VRE has recently increased. Some drugs, such as linezolid and quinupristin/dalfopristin, have been introduced as treatments of VRE infection. However, there is limited information about the effects of VRE-associated CAPD peritonitis. We present a case of successful treatment of CAPD peritonitis caused by VRE with quinupristin/dalfopristin and include a review of the literature.
Sujet(s)
Humains , Acétamides , Incidence , Oxazolidinones , Dialyse péritonéale continue ambulatoire , Péritonite , LinézolideRÉSUMÉ
Duodenal abscess is a form of phlegmonous enterocolitis and is a rarely reported disease throughout the entire world. Duodenal abscess mostly develops from complications of duodenal ulcer perforation, and may result in a clinically fatal course because it is difficult to differentiate from some diseases such as gastric ulcer, gastric cancer, hepatobiliary disorders etc.. The therapeutic gold standard is surgical intervention including abscess removal and drainage. We experienced a case of duodenal abscess that expressed non-specific symptoms, weight loss and epigastric pain, and diagnosed by gastrointestinal endoscopy, abdominal computed tomography. We successfully treated it through surgical intervention with intravenous antibiotics.
Sujet(s)
Abcès , Antibactériens , Cellulite sous-cutanée , Drainage , Ulcère duodénal , Endoscopie gastrointestinale , Entérocolite , Corps étrangers , Tumeurs de l'estomac , Ulcère gastrique , Perte de poidsRÉSUMÉ
Reversible posterior leukoencepalopathy syndrome (RPLS) was noted by a reversible syndrome of headache, altered mental status, seizure, and visual loss associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies. We report a successful treatment of RPLS after secondary ABO incompatibility kidney transplantation with blood pressure control. A 41-year-old female whose primary kidney disease was chronic glomerulonephritis had graft failure developed after living donor kidney transplantation (1st kidney transplantation). She was admitted to our hospital for 2nd ABO incompatibility kidney transplantation. She had undergone 6 times of plasmapheresis and received additional two doses of rituximab (375 mg/m2) and intravenous immunoglobulin (0.5 g/kg) before kidney transplantation. She received basiliximab induction therapy, tacrolimus, steroid and mycophenolate mofetile after transplantation. The ABO antibody titer had been low (below 1:1) and evidences of rejection were not detected. Generalized tonic clonic type seizure, eyeball deviation, facial cyanotic change and loss of consciousness occurred at post operation 7th day. Several minutes later, she recovered her consciousness without disability and neurologic deficit. She did not represent attacks any more after we controlled blood pressure without withdrawal of immunosuppressants or dose reduction.
Sujet(s)
Adulte , Femelle , Humains , Anticorps monoclonaux , Anticorps monoclonaux d'origine murine , Pression sanguine , Conscience , Glomérulonéphrite , Céphalée , Immunoglobulines , Immunosuppresseurs , Rein , Maladies du rein , Transplantation rénale , Leucoencéphalopathies , Donneur vivant , Manifestations neurologiques , Plasmaphérèse , Leucoencéphalopathie postérieure , Protéines de fusion recombinantes , 12481 , Crises épileptiques , Tacrolimus , Transplants , Perte de conscience , RituximabRÉSUMÉ
Focal segmental glomerular sclerosis (FSGS) is known to recur in 20-40% of the renal allografts with graft loss in about half of these cases. We report a successful treatment of a recurrent FSGS after kidney transplantation with rituximab and plasmapheresis. An 16-year-old patient whose primary kidney disease was FSGS developed recurrence of proteinuria after living donor kidney transplantation despite preemptive plasmapheresis and one dose of rituximab (375 mg/m2). After kidney transplantation, nephrotic range proteinuria was detected. Kidney biopsy was done and showed recurrent FSGS. She undergone 11 times of plasmapheresis in the first 4 week post transplantation. In addition, she received additional one dose of rituximab (375 mg/m2) on day 14. Proteinuria was decreased below nephrotic range at 37 day. Ten months later, proteinuria was at 30 mg/day with excellent graft function. No significant adverse events related to rituximab or plasmapheresis were observed. Rituximab with plasmapheresis may be another option for recurrent FSGS after kidney transplantation.